ST elevation myocardial infarction risk stratification and prognosis

Acute Coronary Syndrome Main Page
ST Elevation Myocardial Infarction Microchapters
Home
Patient Information
Overview
Pathophysiology
Pathophysiology of Vessel Occlusion
Pathophysiology of Reperfusion
Gross Pathology
Histopathology
Causes
Differentiating ST elevation myocardial infarction from other Diseases
Epidemiology and Demographics
Risk Factors
Triggers
Natural History and Complications
Risk Stratification and Prognosis
Pregnancy
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
EKG Examples
Chest X Ray
Cardiac MRI
Echocardiography
Coronary Angiography
Treatment
Pre-Hospital Care
Initial Care Oxygen Nitrates Analgesics Aspirin Beta Blockers Antithrombins The coronary care unit The step down unit STEMI and Out-of-Hospital Cardiac Arrest Pharmacologic Reperfusion Reperfusion Therapy (Overview of Fibrinolysis and Primary PCI) Fibrinolysis Reperfusion at a Non–PCI-Capable Hospital:Recommendations Mechanical Reperfusion The importance of reducing Door-to-Balloon times Primary PCI Adjunctive and Rescue PCI Rescue PCI Facilitated PCI Adjunctive PCI CABG Management of Patients Who Were Not Reperfused Assessing Success of Reperfusion Antithrombin Therapy Antithrombin therapy Unfractionated heparin Low Molecular Weight Heparinoid Therapy Direct Thrombin Inhibitor Therapy Factor Xa Inhibition DVT prophylaxis Long term anticoagulation Antiplatelet Agents Aspirin Thienopyridine Therapy Glycoprotein IIbIIIa Inhibition Other Initial Therapy Inhibition of the Renin-Angiotensin-Aldosterone System Magnesium Therapy Glucose Control Calcium Channel Blocker Therapy Lipid Management
Pre-Discharge Care
Recommendations for Perioperative Management–Timing of Elective Noncardiac Surgery in Patients Treated With PCI and DAPT
Post Hospitalization Plan of Care
Long-Term Medical Therapy and Secondary Prevention Overview Inhibition of the Renin-Angiotensin-Aldosterone System Cardiac Rehabilitation Pacemaker Implantation Long Term Anticoagulation Implantable Cardioverter Defibrillator ICD implantation within 40 days of myocardial infarction ICD within 90 days of revascularization
Case Studies
Case #1
Case #2
Case #3
Case #4
Case #5
ST elevation myocardial infarction risk stratification and prognosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on ST elevation myocardial infarction risk stratification and prognosis
CDC on ST elevation myocardial infarction risk stratification and prognosis
ST elevation myocardial infarction risk stratification and prognosis in the news
Blogs on ST elevation myocardial infarction risk stratification and prognosis
Directions to Hospitals Treating ST elevation myocardial infarction
Risk calculators and risk factors for ST elevation myocardial infarction risk stratification and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Two main risk-stratification scores are used when assessing a patient with ST elevation MI and acute coronary syndromes; the TIMI Risk Score (for MI), and the GRACE risk score (for acute coronary syndrome.

Risk Stratification in a Patient with ST Elevation MI

• The Thrombolysis in Myocardial Infarction (TIMI) risk score for STEMI:
  • The TIMI risk score for STEMI was created from simple arithmetic sum of independent predictors of mortality weighted according to the adjusted odds ratios from logistic regression analysis.
  • The patient pool (n=14114) came from the Intravenous nPA for Treatment of Infarcting Myocardium Early II trial (TIME II).
  • The TIMI risk score was subsequently validated in an unselected heterogeneous community population through the National Registry of Myocardial Infarction (NRMI) 3 & 4.
• The Global Registry of Acute Coronary Events (GRACE) risk score for ACS:
  • The GRACE risk score was created from a multivariable logistic regression model using ACS patients enrolled in the GRACE registry (N=11389).
  • The GRACE risk score was validated using subsequent cohort of patients enrolled in GRACE (n=3972) and the Global Use of Strategies to Open Occluded Coronary Arteries IIb (GUSTO-IIb) trial (n=12142).